inclisiran
Pronunciation: in-KLIS-ih-ran
A small interfering RNA therapy that reduces PCSK9 production, administered by injection twice yearly.
Full Definition
Inclisiran is a small interfering RNA (siRNA) therapeutic that targets and degrades PCSK9 messenger RNA in hepatocytes, leading to sustained reduction in PCSK9 protein levels and increased LDL receptor expression. This results in significant and durable LDL cholesterol reduction. The medication is administered subcutaneously twice yearly after an initial loading dose, offering a unique dosing advantage over other PCSK9 inhibitors that require monthly or bi-weekly injections. It represents an important advancement in cardiovascular prevention, particularly for high-risk patients requiring intensive lipid lowering.
Usage
Usage note: Brand name Leqvio; requires subcutaneous injection.
In Context
- "Inclisiran was selected over monthly PCSK9 inhibitors due to its convenient twice-yearly dosing schedule." — Lipid clinic consultation